Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
82 hedge funds and large institutions have $301M invested in Chinook Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 20 reducing their positions, and 12 closing their positions.
586% more call options, than puts
Call options by funds: $803K | Put options by funds: $117K
110% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 20
12% more capital invested
Capital invested by funds: $270M → $301M (+$31.2M)
0% more funds holding
Funds holding: 82 → 82 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$8.19M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$3.01M |
| 3 |
JP Morgan Chase
New York
|
+$2.76M |
| 4 |
BlackRock
New York
|
+$2.29M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$8.6M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$3.21M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.54M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$845K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$633K |
KDNY Hedge Fund Activity: Q2 2017 in Review
82 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2017, worth a combined $301M — up 12% from $270M a quarter earlier.
Fund positioning in KDNY was balanced in Q2 2017: 12 funds opened new positions, 12 closed out, 42 added to existing stakes and 20 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $8.19M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $8.6M sold.
- 82 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $301M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2017, up 12% quarter-over-quarter.
- 12 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2017 and 12 closed out, a net change of 0 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2017 was OppenheimerFunds, an estimated $8.19M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2017 was Ghost Tree Capital, an estimated $8.6M sold.
Based on aggregated 13F filings for Q2 2017.